phrykt

Nuvectis Pharma, Inc. (NVCT): who owns it and who trades it

As of Nov 16, 2026, NVCT insiders reported 2 purchases worth $1.2M in the last 12 months. The largest buyer was Marlio Charles Mosseri (10% owner), with $916K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Nuvectis Pharma

From the latest filings

Overall: more buying than selling. Funds and insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns NVCT

84 funds and institutions reported NVCT shares worth $191M at the end of Q2 2026, about 39% of the company. The largest holder is Tang Capital Management LLC with 5.8%.

Funds and institutions (13F) 39%Everyone else 61%

10 largest owners, by share of the company

Tang Capital Management LLC5.8%
BlackRock, Inc.3.8%
Perceptive Advisors LLC3.8%
Soleus Capital Management, L.P.3.8%
Vanguard Capital Management LLC3.3%
Iridian Asset Management LLC2.9%
Geode Capital Management, LLC1.6%
Sphera Funds Management Ltd.1.4%
Baldwin Wealth Partners LLC1.4%
Occam Crest Management LP1.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Tang Capital Management LLC1.55M5.84%$28.5MNew
BlackRock, Inc.1.00M3.77%$18.4M+31%
Perceptive Advisors LLC1.00M3.77%$18.4MNew
Soleus Capital Management, L.P.1.00M3.77%$18.4MNew
Vanguard Capital Management LLC872,4823.29%$16M+32%
Iridian Asset Management LLC777,0782.93%$14.3M+19%
Geode Capital Management, LLC432,2731.63%$8M+13%
Sphera Funds Management Ltd.382,9451.44%$7MNew
Baldwin Wealth Partners LLC382,0151.44%$7M+1%
Occam Crest Management LP357,1471.35%$7.4M-12%
Alyeska Investment Group, L.P.275,0001.04%$5.1MNew
State Street Corp248,1980.94%$4.6M+49%
Susquehanna International Group, LLP217,2860.82%$4M+106%
Kalehua Capital Management LLC200,0000.75%$3.7MNew
Avidity Partners Management LP200,0000.75%$3.7MNew
Northern Trust Corp146,7140.55%$2.7M+18%
Vanguard Fiduciary Trust Co127,5540.48%$2.3M+11%
Vanguard Portfolio Management LLC118,2970.45%$2.2M+28%
Citadel Advisors LLC115,5320.44%$2.1M+47%
Oppenheimer & Co Inc73,5660.28%$1.4MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, NVCT insiders reported $1.2M of open-market purchases and $0 of sales.

Purchases, 12 months
$1.2M
2 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jun 30, 2026
Filed Jul 1, 2026

Purchases and sales by month

$1.2M$1.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 30, 2026Marlio Charles Mosseri10% ownerPurchase50,000$18.32$916KForm 4
Jun 30, 2026Ron BentsurCEOPurchase12,500$20.00$250KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Marlio Charles Mosseri10% owner$916K–Jun 30, 2026
Ron BentsurChairman & CEO, Director, 10% owner$250K–Jun 30, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

NVCT short interest

Moderate short interest. 7.4% of NVCT shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 78%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.54M NVCT shares were sold short, 7.4% of the shares outstanding, up 6.0% from the report before. At the average daily volume of 167,866 shares, buying them all back would take about 15.2 trading days (days to cover).

Shares short, % of all shares

7.40%May 15Oct 308.10%

Days to cover

15.2May 15Oct 3025.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.54M7.40%+6%167,86615.2
Oct 15, 20262.40M7.37%-5%172,35913.9
Sep 30, 20262.52M7.74%+7%243,82710.3
Sep 15, 20262.36M7.25%+8%159,98914.8
Aug 31, 20262.20M6.74%+20%235,4659.3
Aug 14, 20261.84M5.64%-0%200,6169.2
Jul 31, 20261.84M5.66%+22%249,0627.4
Jul 15, 20261.51M5.70%-16%377,7284.0
Jun 30, 20261.80M6.80%+15%788,9112.3
Jun 15, 20261.57M5.92%-1%69,33422.6
May 29, 20261.58M5.96%+11%116,04413.6
May 15, 20261.43M5.38%-3%130,23810.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Nuvectis Pharma company events

Nuvectis Pharma filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Aug 21, 2026AnnouncementNuvectis Pharma, Inc., a Delaware corporation, entered into an Open Market Sale Agreement SM with Jefferies LLC as sales agent, pursuant to which the Company may offer and sell shares of its common stock, $0.00001 par value per share, from time to time through Jefferies. Filing
  3. Aug 4, 2026ResultsReleased financial results. Filing
  4. Jun 30, 2026AgreementNuvectis Pharma, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. Filing
  5. Jun 29, 2026AnnouncementAs previously disclosed, on May 9, 2025, Nuvectis Pharma, Inc. entered into a Sales Agreement with Leerink Partners LLC pursuant to which the Company may sell, from time to time, at its option, shares of the Company’s common stock, under a prospectus through the Agent. Filing
  6. Jun 23, 2026AgreementNuvectis Pharma, Inc., a Delaware corporation, entered into a license agreement with Haisco Pharmaceutical Group Co., Ltd. Filing
  7. Jun 12, 2026VoteReported shareholder vote results. Filing
  8. May 5, 2026ResultsReleased financial results. Filing
  9. Feb 11, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Nuvectis Pharma financials

Famous investors that hold NVCT

2 of the 50 well-known investors we track reported holding NVCT in their latest 13F filing. The largest position is Steve Cohen's, worth $976K.

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 202646,229$976K0.0%New
Ken Griffin · Citadel AdvisorsQ3 202643,940$928K0.0%-62%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Nuvectis Pharma, Inc. (NVCT) stock

Who owns the most NVCT stock?

The largest reported owner of Nuvectis Pharma, Inc. (NVCT) is Tang Capital Management LLC, with 5.8% of the company. In total, 84 funds and institutions reported holding NVCT at the end of Q2 2026, together about 39% of the shares. See the largest owners.

Are NVCT insiders buying or selling?

In the last 12 months, NVCT insiders reported 2 open-market purchases worth $1.2M and no sales. The latest trade was on Jun 30, 2026. See every trade.

What is the short interest in NVCT?

As of Oct 30, 2026, 2.54M NVCT shares were sold short, 7.4% of the shares outstanding, up 6.0% from the report before. At the average daily volume of 167,866 shares, buying them all back would take about 15.2 trading days (days to cover). See the history.

Which famous investors hold NVCT?

2 of the 50 well-known investors we track reported NVCT in their latest 13F filing, including Steve Cohen, Ken Griffin. The largest position is worth $976K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.